English Polski
Online first
Review paper
Published online: 2024-05-17
Page views 122
Article views/downloads 6
Get Citation

Connect on Social Media

Connect on Social Media

The therapeutic potential of selected narcotic substances — a review of recent research

Anna Stankiewicz1, Jan Szewczyk1, Julia Truszkowska1, Stefan Modzelewski2, Napoleon Waszkiewicz2

Abstract

Terapie farmakologiczne wielu schorzeń psychiatrycznych nie spełniają oczekiwań pacjentów. Poszukiwane są nowe środki do leczenia m.in. depresji i zaburzeń lękowych. Naukowe zainteresowanie substancjami psychoaktywnymi wzrosło w ciągu ostatnich kilku dekad. Najnowsze badania dostarczają dowodów na to, że psychodeliki mogą znaleźć zastosowanie w leczeniu szeregu zaburzeń psychicznych. W niniejszym artykule opisano nowe badania przeprowadzone od 2019 r. nad najpopularniejszymi psychodelikami: LSD, MDMA, psylocybiny i THC. Analiza została rozszerzona o substancje mniej popularne w użytku rekreacyjnym i naukowym, takie jak 5-MeO-DMT, dekstrometorfan, DMT, ibogaina, ketamina i meskalina. Wydaje się, że opisane halucynogeny wykazują potencjał terapeutyczny w leczeniu uzależnień (nikotyna, alkohol i uzależnienie od substancji), depresji, lęku (w tym lęku współistniejącego w zaburzeniach ze spektrum autyzmu), PTSD, zaburzeń odżywiania i zespołu Tourette'a. Po opracowaniu odpowiednich protokołów, środki psychoaktywne mogą stać się elementem kompleksowej i skutecznej terapii.

Article available in PDF format

Add to basket: 49.00 PLN

Aready have access?

References

  1. Derakhshanian S, Zhou M, Rath A, et al. Role of ketamine in the treatment of psychiatric disorders. Health Psychol Res. 2021; 9(1): 25091.
  2. Król B, Szewczak B, Rozenek EB, et al. Therapeutic use of selected psychoactive substances. Psychiatria. 2019; 16(3): 154–62.
  3. Kargbo RB. Psilocybin therapeutic research: the present and future paradigm. ACS Med Chem Lett. 2020; 11(4): 399–402.
  4. Rodrigues AV, Almeida FJ, Vieira-Coelho MA. Dimethyltryptamine: endogenous role and therapeutic potential. J Psychoactive Drugs. 2019; 51(4): 299–310.
  5. Pic-Taylor A, da Motta LG, de Morais JA, et al. Behavioural and neurotoxic effects of ayahuasca infusion (Banisteriopsis caapi and Psychotria viridis) in female Wistar rat. Behav Processes. 2015; 118: 102–110.
  6. D'Souza DC, Syed SA, Flynn LT, et al. Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder. Neuropsychopharmacology. 2022; 47(10): 1854–1862.
  7. Dos Santos RG, Hallak JE. Ayahuasca, an ancient substance with traditional and contemporary use in neuropsychiatry and neuroscience. Epilepsy Behav. 2021; 121(Pt B): 106300.
  8. Palhano-Fontes F, Barreto D, Onias H, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019; 49(4): 655–663.
  9. Uthaug MV, Mason NL, Toennes SW, et al. A placebo-controlled study of the effects of ayahuasca, set and setting on mental health of participants in ayahuasca group retreats. Psychopharmacology (Berl). 2021; 238(7): 1899–1910.
  10. Libânio Osório Marta RF. Metabolism of lysergic acid diethylamide (LSD): an update. Drug Metab Rev. 2019; 51(3): 378–387.
  11. Family N, Maillet EL, Williams LTJ, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers. Psychopharmacology (Berl). 2020; 237(3): 841–853.
  12. Moda-Sava RN, Murdock MH, Parekh PK, et al. Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. Science. 2019; 364(6436).
  13. Krebs TS, Johansen PØ. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol. 2012; 26(7): 994–1002.
  14. Holze F, Gasser P, Müller F, et al. Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study. Biol Psychiatry. 2023; 93(3): 215–223.
  15. Davis AK, So S, Lancelotta R, et al. 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. Am J Drug Alcohol Abuse. 2019; 45(2): 161–169.
  16. El-Seedi HR, De Smet PA, Beck O, et al. Prehistoric peyote use: alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas. J Ethnopharmacol. 2005; 101(1-3): 238–242.
  17. Dinis-Oliveira RJ, Pereira CL, da Silva DD. Pharmacokinetic and pharmacodynamic aspects of peyote and mescaline: clinical and forensic repercussions. Curr Mol Pharmacol. 2019; 12(3): 184–194.
  18. Agin-Liebes G, Haas TF, Lancelotta R, et al. Naturalistic use of mescaline is associated with self-reported psychiatric improvements and enduring positive life changes. ACS Pharmacol Transl Sci. 2021; 4(2): 543–552.
  19. Lowe H, Toyang N, Steele B, et al. The therapeutic potential of psilocybin. Molecules. 2021; 26(10).
  20. Sarparast A, Thomas K, Malcolm B, et al. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology (Berl). 2022; 239(6): 1945–1976.
  21. Carhart-Harris RL, Bolstridge M, Day CMJ, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl). 2018; 235(2): 399–408.
  22. Gukasyan N, Davis AK, Barrett FS, et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. J Psychopharmacol. 2022; 36(2): 151–158.
  23. MacCallum CA, Lo LA, Pistawka CA, et al. Therapeutic use of psilocybin: Practical considerations for dosing and administration. Front Psychiatry. 2022; 13: 1040217.
  24. van der Meer PB, Fuentes JJ, Kaptein AdA, et al. Therapeutic effect of psilocybin in addiction: a systematic review. Front Psychiatry. 2023; 14: 1134454.
  25. Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2022; 79(10): 953–962.
  26. Peck SK, Shao S, Gruen T, et al. Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Nat Med. 2023; 29(8): 1947–1953.
  27. Shen HW, Jiang XL, Winter JC, et al. Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. Curr Drug Metab. 2010; 11(8): 659–666.
  28. Davis AK, Barsuglia JP, Lancelotta R, et al. The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: benefits, consequences, patterns of use, subjective effects, and reasons for consumption. J Psychopharmacol. 2018; 32(7): 779–792.
  29. Uthaug MV, Lancelotta R, van Oorsouw K, et al. A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms. Psychopharmacology (Berl). 2019; 236(9): 2653–2666.
  30. Reckweg JT, van Leeuwen CJ, Henquet C, et al. A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression. Front Psychiatry. 2023; 14: 1133414.
  31. Barsuglia J, Davis AK, Palmer R, et al. Intensity of mystical experiences occasioned by 5-MeO-DMT and comparison with a prior psilocybin study. Front Psychol. 2018; 9: 2459.
  32. Kverno K. Dextromethorphan: from cough suppressant to antidepressant. J Psychosoc Nurs Ment Health Serv. 2022; 60(11): 9–11.
  33. Steinmiller CL, Maisonneuve IM, Glick SD. Effects of dextromethorphan on dopamine release in the nucleus accumbens: Interactions with morphine. Pharmacol Biochem Behav. 2003; 74(4): 803–810.
  34. Iosifescu DV, Jones A, O'Gorman C, et al. Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI). J Clin Psychiatry. 2022; 83(4).
  35. Tabuteau H, Jones A, Anderson A, et al. Effect of AXS-05 (dextromethorphan-bupropion) in major depressive disorder: a randomized double-blind controlled trial. Am J Psychiatry. 2022; 179(7): 490–499.
  36. Bem JL, Peck R. Dextromethorphan. An overview of safety issues. Drug Saf. 1992; 7(3): 190–199.
  37. Meisner JA, Wilcox SR, Richards JB. Ibogaine-associated cardiac arrest and death: case report and review of the literature. Ther Adv Psychopharmacol. 2016; 6(2): 95–98.
  38. Litjens RPW, Brunt TM. How toxic is ibogaine? Clin Toxicol (Phila). 2016; 54(4): 297–302.
  39. Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018; 44(1): 37–46.
  40. Jelen LA, Young AH, Stone JM. Ketamine: a tale of two enantiomers. J Psychopharmacol. 2021; 35(2): 109–123.
  41. Carrillo P, Petit AC, Gaillard R, et al. The next psychoactive drugs: from imipramine to ketamine. Bull Acad Natl Med. 2020; 204(9): e169–e177.
  42. Zanos P, Gould TD. Mechanisms of ketamine action as an antidepressant. Mol Psychiatry. 2018; 23(4): 801–811.
  43. Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2018; 75(2): 139–148.
  44. Fedgchin M, Trivedi M, Daly EJ, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019; 22(10): 616–630.
  45. Singh JB, Fedgchin M, Daly E, et al. Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatry. 2016; 80(6): 424–431.
  46. Phillips JL, Norris S, Talbot J, et al. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. Neuropsychopharmacology. 2020; 45(4): 606–612.
  47. Bernschneider-Reif S, Oxler F, Freudenmann RW. The origin of MDMA ("ecstasy") — separating the facts from the myth. Pharmazie. 2006; 61(11): 966–972.
  48. Passie T, Benzenhöfer U. The history of MDMA as an underground drug in the united states, 1960–1979. J Psychoactive Drugs. 2016; 48(2): 67–75.
  49. Underhill SM, Hullihen PD, Chen J, et al. Amphetamines signal through intracellular TAAR1 receptors coupled to Gα and Gα in discrete subcellular domains. Mol Psychiatry. 2021; 26(4): 1208–1223.
  50. Lizarraga LE, Cholanians AB, Phan AV, et al. Vesicular monoamine transporter 2 and the acute and long-term response to 3,4-(±)-methylenedioxymethamphetamine. Toxicol Sci. 2015; 143(1): 209–219.
  51. Strober B, Stein Gold L, Bissonnette R, et al. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: results from the PSOARING 3 trial. J Am Acad Dermatol. 2022; 87(4): 800–806.
  52. Mitchell JM, Bogenschutz M, Lilienstein A, et al. MDMA-Assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Focus (Am Psychiatr Publ). 2023; 21(3): 315–328.
  53. Nicholas CR, Wang JB, Coker A, et al. The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD. Drug Alcohol Depend. 2022; 233: 109356.
  54. Brewerton TD, Lafrance A, Mithoefer MC. The potential use of N-methyl-3,4-methylenedioxyamphetamine (MDMA) assisted psychotherapy in the treatment of eating disorders comorbid with PTSD. Med Hypotheses. 2021; 146: 110367.
  55. Chaliha D, Mamo JC, Albrecht M, et al. A systematic review of the MDMA model to address social impairment in autism. Curr Neuropharmacol. 2021; 19(7): 1101–1154.
  56. Danforth AL. Embracing neurodiversity in psychedelic science: a mixed-methods inquiry into the MDMA experiences of autistic adults. J Psychoactive Drugs. 2019; 51(2): 146–154.
  57. Psiuk D, Nowak E, Cholewa K, et al. The potential role of serotonergic hallucinogens in depression treatment. Life (Basel). 2021; 11(8).
  58. Jones GM, Nock MK. MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults. J Psychopharmacol. 2022; 36(1): 46–56.
  59. Burgess C, O'Donohoe A, Gill M. Agony and ecstasy: a review of MDMA effects and toxicity. Eur Psychiatry. 2000; 15(5): 287–294.
  60. Mitchell JM, Bogenschutz M, Lilienstein A, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021; 27(6): 1025–1033.
  61. Crocq MA. History of cannabis and the endocannabinoid system. Dialogues Clin Neurosci. 2020; 22(3): 223–228.
  62. Gilman JM, Schmitt WA, Potter K, et al. Identification of ∆9-tetrahydrocannabinol (THC) impairment using functional brain imaging. Neuropsychopharmacology. 2022; 47(4): 944–952.
  63. Cristino L, Bisogno T, Di Marzo V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol. 2020; 16(1): 9–29.
  64. Mayo LM, Rabinak CA, Hill MN, et al. Targeting the endocannabinoid system in the treatment of posttraumatic stress disorder: a promising case of preclinical-clinical translation? Biol Psychiatry. 2022; 91(3): 262–272.
  65. Martin EL, Strickland JC, Schlienz NJ, et al. Antidepressant and anxiolytic effects of medicinal cannabis use in an observational trial. Front Psychiatry. 2021; 12: 729800.
  66. Zabik NL, Rabinak CA, Peters CA, et al. Cannabinoid modulation of corticolimbic activation during extinction learning and fear renewal in adults with posttraumatic stress disorder. Neurobiol Learn Mem. 2023; 201: 107758.
  67. Esketamine nasal spray for treatment‐resistant depression. Med Lett Drugs Ther. 2019; 61(1569): 54–57.
  68. Haridy R. Australia to prescribe MDMA and psilocybin for PTSD and depression in world first. Nature. 2023; 619(7969): 227–228.